NCT06603818View on ClinicalTrials.gov

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

June 1, 2027

Conditions
Microsatellite Stable Metastatic Colorectal CancerMetastatic Colorectal CancerColorectal Cancer
Interventions
BIOLOGICAL

Tiragolumab

Tiragolumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years

BIOLOGICAL

Atezolizumab

Atezolizumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

SBRT will occur on Days 1, 3, and 5 of Cycle 1 only

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT06603818 - Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) | Biotech Hunter | Biotech Hunter